🚀 VC round data is live in beta, check it out!
Easywell Biomedicals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Easywell Biomedicals and similar public comparables like Tenaya Therapeutics, Dimerix, Black Diamond Therapeutics, Panion & Bf Biotech and more.
Easywell Biomedicals Overview
About Easywell Biomedicals
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. The company's segments include the Drug Development segment and the Other segment.
Founded
1998
HQ
Employees
17
Website
Sectors
Financials (FY)
EV
$172M
Easywell Biomedicals Financials
Easywell Biomedicals reported last fiscal year revenue of $19M and EBITDA of $1M.
In the same fiscal year, Easywell Biomedicals generated $9M in gross profit, $1M in EBITDA, and had net loss of ($2M).
Easywell Biomedicals P&L
In the most recent fiscal year, Easywell Biomedicals reported revenue of $19M and EBITDA of $1M.
Easywell Biomedicals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $9M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 47% | XXX | XXX | XXX |
| EBITDA | — | XXX | $1M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 6% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (12%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (12%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Easywell Biomedicals Stock Performance
Easywell Biomedicals has current market cap of $173M, and enterprise value of $172M.
Market Cap Evolution
Easywell Biomedicals' stock price is $1.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $172M | $173M | 0.5% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEasywell Biomedicals Valuation Multiples
Easywell Biomedicals trades at 9.0x EV/Revenue multiple, and 140.5x EV/EBITDA.
Easywell Biomedicals Financial Valuation Multiples
As of April 19, 2026, Easywell Biomedicals has market cap of $173M and EV of $172M.
Equity research analysts estimate Easywell Biomedicals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Easywell Biomedicals has a P/E ratio of (74.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $173M | XXX | $173M | XXX | XXX | XXX |
| EV (current) | $172M | XXX | $172M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 9.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 140.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (77.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 19.3x | XXX | XXX | XXX |
| P/E | — | XXX | (74.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 49.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Easywell Biomedicals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Easywell Biomedicals Margins & Growth Rates
Easywell Biomedicals' revenue in the last fiscal year grew by 11%.
Easywell Biomedicals' revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.7M for the same period.
Easywell Biomedicals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 201% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 40% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Easywell Biomedicals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Easywell Biomedicals | XXX | XXX | XXX | XXX | XXX | XXX |
| Tenaya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dimerix | XXX | XXX | XXX | XXX | XXX | XXX |
| Black Diamond Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Panion & Bf Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Unicycive | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Easywell Biomedicals M&A Activity
Easywell Biomedicals acquired XXX companies to date.
Last acquisition by Easywell Biomedicals was on XXXXXXXX, XXXXX. Easywell Biomedicals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Easywell Biomedicals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEasywell Biomedicals Investment Activity
Easywell Biomedicals invested in XXX companies to date.
Easywell Biomedicals made its latest investment on XXXXXXXX, XXXXX. Easywell Biomedicals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Easywell Biomedicals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Easywell Biomedicals
| When was Easywell Biomedicals founded? | Easywell Biomedicals was founded in 1998. |
| Where is Easywell Biomedicals headquartered? | Easywell Biomedicals is headquartered in Taiwan. |
| How many employees does Easywell Biomedicals have? | As of today, Easywell Biomedicals has over 17 employees. |
| Is Easywell Biomedicals publicly listed? | Yes, Easywell Biomedicals is a public company listed on Taipei Exchange. |
| What is the stock symbol of Easywell Biomedicals? | Easywell Biomedicals trades under 1799 ticker. |
| When did Easywell Biomedicals go public? | Easywell Biomedicals went public in 2008. |
| Who are competitors of Easywell Biomedicals? | Easywell Biomedicals main competitors are Tenaya Therapeutics, Dimerix, Black Diamond Therapeutics, Panion & Bf Biotech. |
| What is the current market cap of Easywell Biomedicals? | Easywell Biomedicals' current market cap is $173M. |
| What is the current revenue of Easywell Biomedicals? | Easywell Biomedicals' last fiscal year revenue is $19M. |
| What is the current EV/Revenue multiple of Easywell Biomedicals? | Current revenue multiple of Easywell Biomedicals is 9.0x. |
| Is Easywell Biomedicals profitable? | No, Easywell Biomedicals is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.